Skip to main content
Figure 1 | Journal of Translational Medicine

Figure 1

From: Increased levels of choline metabolites are an early marker of docetaxel treatment response in BRCA1-mutated mouse mammary tumors: an assessment by ex vivo proton magnetic resonance spectroscopy

Figure 1

1 H HRMAS spectra and Principal Component Analysis (PCA) of control tumor samples. A: The mean spectra of resistant tumor (red) show increased choline compounds compared to those of sensitive tumors (blue). B: Biplot [42] showing PCA analysis of HRMAS spectra. Docetaxel sensitive samples are shown with black triangle and resistant samples with squares. Arrows are drawn based on the loading plots to show the important metabolites responsible for the demarcation between the groups. Resistant samples have higher levels of GPC, PCho and Choline.

Back to article page